Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Christian D Young

TitleAsst Professor-Research
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Pathology

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Boss MK, Ke Y, Bian L, Harrison LG, Lee BI, Prebble A, Martin T, Trageser E, Hall S, Wang DD, Wang S, Chow L, Holwerda B, Raben D, Regan D, Karam SD, Dow S, Young CD, Wang XJ. Therapeutic Intervention Using a Smad7-Based Tat Protein to Treat Radiation-Induced Oral Mucositis. Int J Radiat Oncol Biol Phys. 2021 Oct 03. PMID: 34610386.
      View in: PubMed
    2. Shi X, Luo J, Weigel KJ, Hall SC, Du D, Wu F, Rudolph MC, Zhou H, Young CD, Wang XJ. Cancer-Associated Fibroblasts Facilitate Squamous Cell Carcinoma Lung Metastasis in Mice by Providing TGFß-Mediated Cancer Stem Cell Niche. Front Cell Dev Biol. 2021; 9:668164. PMID: 34527666.
      View in: PubMed
    3. Strait AA, Woolaver RA, Hall SC, Young CD, Karam SD, Jimeno A, Lan Y, Raben D, Wang JH, Wang XJ. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFß/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol. 2021 08 25; 4(1):1005. PMID: 34433873.
      View in: PubMed
    4. Shi X, Young CD, Zhou H, Wang X. Transforming Growth Factor-ß Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts. Biomolecules. 2020 12 12; 10(12). PMID: 33322749.
      View in: PubMed
    5. Chen SMY, Li B, Nicklawsky AG, Krinsky AL, Brunetti T, Woolaver RA, Wang X, Chen Z, Young CD, Gao D, Wang XJ, Wang JH. Deletion of p53 and Hyper-Activation of PIK3CA in Keratin-15+ Stem Cells Lead to the Development of Spontaneous Squamous Cell Carcinoma. Int J Mol Sci. 2020 Sep 09; 21(18). PMID: 32916850.
      View in: PubMed
    6. Nolan K, Verzosa G, Cleaver T, Tippimanchai D, DePledge LN, Wang XJ, Young C, Le A, Doebele R, Li H, Malkoski SP. Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models. Cancer Cell Int. 2020; 20:417. PMID: 32874131.
      View in: PubMed
    7. Gomez KE, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, Le PN, Nieto C, Chowdhury FN, Tyagi A, Lyons TR, Young CD, Zhou H, Somerset HL, Wang XJ, Jimeno A. Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells. Cancer Res. 2020 10 01; 80(19):4185-4198. PMID: 32816856.
      View in: PubMed
    8. Hernandez AL, Young CD, Bian L, Weigel K, Nolan K, Frederick B, Han G, He G, Devon Trahan G, Rudolph MC, Jones KL, Oweida AJ, Karam SD, Raben D, Wang XJ. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res. 2020 06 15; 26(12):3058-3070. PMID: 32139402.
      View in: PubMed
    9. Wu FL, Nolan K, Strait AA, Bian L, Nguyen KA, Wang JH, Jimeno A, Zhou HM, Young CD, Wang XJ. Macrophages Promote Growth of Squamous Cancer Independent of T cells. J Dent Res. 2019 07; 98(8):896-903. PMID: 31189369.
      View in: PubMed
    10. Hernandez AL, Young CD, Wang JH, Wang XJ. Lessons learned from SMAD4 loss in squamous cell carcinomas. Mol Carcinog. 2019 09; 58(9):1648-1655. PMID: 31140647.
      View in: PubMed
    11. Li F, Bian L, Iriyama S, Jian Z, Fan B, Luo J, Wang DD, Young CD, Han G, Wang XJ. Smad7 Ameliorates TGF-ß-Mediated Skin Inflammation and Associated Wound Healing Defects but Not Susceptibility to Experimental Skin Carcinogenesis. J Invest Dermatol. 2019 04; 139(4):940-950. PMID: 30423327.
      View in: PubMed
    12. Luo J, Bian L, Blevins MA, Wang D, Liang C, Du D, Wu F, Holwerda B, Zhao R, Raben D, Zhou H, Young CD, Wang XJ. Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model. Clin Cancer Res. 2019 01 15; 25(2):808-818. PMID: 30185419.
      View in: PubMed
    13. Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018 10 15; 24(20):4949-4959. PMID: 30084837.
      View in: PubMed
    14. Bhatia S, Griego A, Lennon S, Oweida A, Sharma J, Rohmer C, Uyanga N, Bukkapatnam S, Van Court B, Raben D, Young C, Heasley L, Karam SD. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. . 2018 09; 17(9):2049-2059. PMID: 29970482.
      View in: PubMed
    15. Luo JJ, Young CD, Zhou HM, Wang XJ. Mouse Models for Studying Oral Cancer: Impact in the Era of Cancer Immunotherapy. J Dent Res. 2018 06; 97(6):683-690. PMID: 29649368.
      View in: PubMed
    16. Tippimanchai DD, Nolan K, Poczobutt J, Verzosa G, Li H, Scarborough H, Huang J, Young C, DeGregori J, Nemenoff RA, Malkoski SP. Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology. 2018; 7(6):e1438105. PMID: 29872579.
      View in: PubMed
    17. Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. J Natl Cancer Inst. 2017 11 01; 109(11). PMID: 29059433.
      View in: PubMed
    18. Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, G?mez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL. Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017 Aug 09; 9(402). PMID: 28794284.
      View in: PubMed
    19. Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CL. Association of FGFR1 with ERa Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clin Cancer Res. 2017 Oct 15; 23(20):6138-6150. PMID: 28751448.
      View in: PubMed
    20. Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res. 2017 Jun 30; 19(1):74. PMID: 28666462.
      View in: PubMed
    21. Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Res. 2016 08 15; 76(16):4752-64. PMID: 27197158.
      View in: PubMed
    22. Young CD, Arteaga CL, Cook RS. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Breast Cancer Res. 2015 Dec 04; 17:148. PMID: 26637440.
      View in: PubMed
    23. Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett. 2015 Nov 01; 368(1):79-87. PMID: 26235139.
      View in: PubMed
    24. Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. PLoS Genet. 2015 Jul; 11(7):e1005291. PMID: 26132202.
      View in: PubMed
    25. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Mol Cell Proteomics. 2015 Jul; 14(7):1959-76. PMID: 25953087.
      View in: PubMed
    26. Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS, Cook RS. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest. 2014 Nov; 124(11):4737-52. PMID: 25250573.
      View in: PubMed
    27. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014 Feb; 4(2):232-45. PMID: 24356096.
      View in: PubMed
    28. Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest. 2013 Oct; 123(10):4329-43. PMID: 23999432.
      View in: PubMed
    29. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013 Aug 27; 110(35):14372-7. PMID: 23940356.
      View in: PubMed
    30. Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res. 2013 Jul 01; 73(13):4075-85. PMID: 23633485.
      View in: PubMed
    31. Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, Cook RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012 May 15; 72(10):2672-82. PMID: 22461506.
      View in: PubMed
    32. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc Natl Acad Sci U S A. 2012 Jan 03; 109(1):221-6. PMID: 22178756.
      View in: PubMed
    33. Young CD, Lewis AS, Rudolph MC, Ruehle MD, Jackman MR, Yun UJ, Ilkun O, Pereira R, Abel ED, Anderson SM. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PLoS One. 2011; 6(8):e23205. PMID: 21826239.
      View in: PubMed
    34. Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res. 2011 Jun 01; 71(11):3941-51. PMID: 21482676.
      View in: PubMed
    35. Lambert JR, Eddy VJ, Young CD, Persons KS, Sarkar S, Kelly JA, Genova E, Lucia MS, Faller DV, Ray R. A vitamin D receptor-alkylating derivative of 1a,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila). 2010 Dec; 3(12):1596-607. PMID: 21149334.
      View in: PubMed
    36. Nelson AC, Lyons TR, Young CD, Hansen KC, Anderson SM, Holt JT. AKT regulates BRCA1 stability in response to hormone signaling. Mol Cell Endocrinol. 2010 May 05; 319(1-2):129-42. PMID: 20085797.
      View in: PubMed
    37. Young CD, Anderson SM. Rah, rah, ROS: metabolic changes caused by loss of adhesion induce cell death. Breast Cancer Res. 2009; 11(6):307. PMID: 19930622.
      View in: PubMed
    38. Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res. 2008; 10(4):R70. PMID: 18700973.
      View in: PubMed
    39. Young CD, Anderson SM. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res. 2008; 10(1):202. PMID: 18304378.
      View in: PubMed
    40. Lambert JR, Young CD, Persons KS, Ray R. Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D3 derivative in prostate cancer cells. Biochem Biophys Res Commun. 2007 Sep 14; 361(1):189-95. PMID: 17658477.
      View in: PubMed
    41. Young C, Mapes J, Hanneman J, Al-Zarban S, Ota I. Role of Ptc2 type 2C Ser/Thr phosphatase in yeast high-osmolarity glycerol pathway inactivation. Eukaryot Cell. 2002 Dec; 1(6):1032-40. PMID: 12477803.
      View in: PubMed
    Young's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)